The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
US9187424, 6-2 ID: ALA3893594
Chembl Id: CHEMBL3893594
PubChem CID: 71582673
Max Phase: Preclinical
Molecular Formula: C31H28F6N2O4
Molecular Weight: 606.56
Molecule Type: Small molecule
Associated Items:
Names and Identifiers Canonical SMILES: COc1ccc(NC(=O)C2=C(c3ccc(C)cc3)C[C@](c3ccc(OCCCC(F)(F)F)cc3)(C(F)(F)F)NC2=O)cc1
Standard InChI: InChI=1S/C31H28F6N2O4/c1-19-4-6-20(7-5-19)25-18-29(31(35,36)37,21-8-12-24(13-9-21)43-17-3-16-30(32,33)34)39-28(41)26(25)27(40)38-22-10-14-23(42-2)15-11-22/h4-15H,3,16-18H2,1-2H3,(H,38,40)(H,39,41)/t29-/m0/s1
Standard InChI Key: FBBPRPJENPWDPL-LJAQVGFWSA-N
Associated Targets(Human) Associated Targets(non-human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 606.56Molecular Weight (Monoisotopic): 606.1953AlogP: 7.09#Rotatable Bonds: 9Polar Surface Area: 76.66Molecular Species: NEUTRALHBA: 4HBD: 2#RO5 Violations: 2HBA (Lipinski): 6HBD (Lipinski): 2#RO5 Violations (Lipinski): 2CX Acidic pKa: 9.97CX Basic pKa: ┄CX LogP: 6.78CX LogD: 6.77Aromatic Rings: 3Heavy Atoms: 43QED Weighted: 0.15Np Likeness Score: -0.58
References 1. (2015) Aryl dihydropyridinones and piperidinone MGAT2 inhibitors, 2. Turdi H, Chao H, Hangeland JJ, Ahmad S, Meng W, Brigance R, Zhao G, Wang W, Moore F, Ye XY, Mathur A, Hou X, Kempson J, Wu DR, Li YX, Azzara AV, Ma Z, Chu CH, Chen L, Cullen MJ, Rooney S, Harvey S, Kopcho L, Panemangelor R, Abell L, O'Malley K, Keim WJ, Dierks E, Chang S, Foster K, Apedo A, Harden D, Dabros M, Gao Q, Pelleymounter MA, Whaley JM, Robl JA, Cheng D, Lawrence RM, Devasthale P.. (2021) Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders., 64 (19.0): [PMID:34613725 ] [10.1021/acs.jmedchem.1c01356 ]